Latest Breaking News On - Asahi kasei pharma - Page 8 : comparemela.com

VectivBio Enters Licensing Deal with Asahi Kasei and $100 Million Plus in New Funding

VectivBio Enters Licensing Deal with Asahi Kasei and $100 Million Plus in New Funding
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesYoshikazu aokiLuca santarelliAsahi kasei pharmaEuropean unionAcute graft versus host diseaseAsahi kaseiKreos capital

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial. | March 30, 2022

Yoshikazu aokiClaudia daugustaLuca santarelliAsahi kasei pharmaMaurizio petitbonExchange commissionExchange commission onAsahi kasei pharma corporationAsahi kasei pharma missionVectivbio holding ag nasdaqExclusive licenseKreos capitalBusiness updateChief executive officerAsahi kaseiGeneral partner

Commercial and Labor & Employment Trial Lawyer Christopher Banks Joins Crowell & Moring

SAN FRANCISCO , Feb. 23, 2022 /PRNewswire/ Christopher J. Banks joins Crowell & Moring s San Francisco office as a partner in its Litigation an.

United statesKris meadePrnewswire christopherJennifer romanoAsahi kaseiPhilipt inglimaAsahi kasei pharma corpCrowell moring labor employment groupSenior communicationsGeorgetown university law centerUniversity of nebraskaCrowell moring litigation groupCrowell moringGeorge washington universityNational law journalCalifornia supreme court

Basilea to become a leading anti-infectives company backed

65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives.

Basel stadtAsahi kasei pharmaDavid veitchNicole onettoThomas wernerCresemba zevteraMartin nicklassonDomenico scalaLeonard kruimerStevend skolskyAdesh kaulNational medical products administrationBasilea pharmaceutica ltdChief executive officerChief financial officerBasilea pharmaceutica

Basilea Pharmaceutica AG: Basilea to become a leading anti-infectives company backed by strong financial results 2021

65% year-on-year growth in non-deferred revenue from Cresemba and Zevtera Operating profit of CHF 1.2 million Future strategic focus on anti-infectives Exploring strategic options to maximize the value

United statesBasel stadtNils schrAsahi kasei pharmaDavid veitchNicole onettoThomas wernerDomenico scalaCresemba zevteraMartin nicklassonLeonard kruimerAdesh kaulStevend skolskyHead of corporate communications investor relationsArqule incMerck co inc